Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DART 2.0: ctHPV-DNA Informed De-Escalated Adjuvant and Definitive Radiation Therapy

NCT05541016 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05541016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05541016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DART 2.0: ctHPV-DNA Informed De-Escalated Adjuvant and Definitive Radiation Therapy
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
March 20, 2023
Completion date
September 6, 2029
Enrollment
455 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage i hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage ii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, human papillomavirus-related oropharyngeal squamous cell carcinoma, stage i oropharyngeal (p16-negative) carcinoma ajcc v8, stage ii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iii oropharyngeal (p16-negative) carcinoma ajcc v8